Novo Nordisk Abandons Kidney Disease Drug from $1.3 Billion Acquisition After Phase 3 Setback
Novo Nordisk has officially pulled the plug on ocedurenone, a promising kidney disease drug acquired for $1.3 billion from KBP ...
Novo Nordisk has officially pulled the plug on ocedurenone, a promising kidney disease drug acquired for $1.3 billion from KBP ...
© 2020 The Lagos Today - Nkali.